
G1 Therapeutics Inc
NASDAQ:GTHX

Intrinsic Value
The intrinsic value of one
GTHX
stock under the Base Case scenario is
5.49
USD.
Compared to the current market price of 7.15 USD,
G1 Therapeutics Inc
is
Overvalued by 23%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
G1 Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
G1 Therapeutics Inc
Balance Sheet Decomposition
G1 Therapeutics Inc
Current Assets | 92.9m |
Cash & Short-Term Investments | 60.7m |
Receivables | 13.3m |
Other Current Assets | 18.9m |
Non-Current Assets | 5.8m |
PP&E | 5.6m |
Other Non-Current Assets | 187k |
Free Cash Flow Analysis
G1 Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
G1 Therapeutics Inc
Revenue
|
58.2m
USD
|
Cost of Revenue
|
-6.1m
USD
|
Gross Profit
|
52m
USD
|
Operating Expenses
|
-89.9m
USD
|
Operating Income
|
-37.9m
USD
|
Other Expenses
|
-6.9m
USD
|
Net Income
|
-44.8m
USD
|
GTHX Profitability Score
Profitability Due Diligence
G1 Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Score
G1 Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
GTHX Solvency Score
Solvency Due Diligence
G1 Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Score
G1 Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GTHX Price Targets Summary
G1 Therapeutics Inc
Dividends
Current shareholder yield for GTHX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
GTHX
stock under the Base Case scenario is
5.49
USD.
Compared to the current market price of 7.15 USD,
G1 Therapeutics Inc
is
Overvalued by 23%.